Instrumento Inactivo

Acciones Raptor Pharmaceutical Corp

Acciones

Precio de cierre Nasdaq Otros sitios de cotización
- ^USD	-

Depomed : Le laboratoire Depomed résigné à se vendre-sources	16/09/16
Exclusive: Drugmaker Depomed prepares to explore a sale - sources	15/09/16
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Shareholders To Contact The Firm For Additional Information	15/09/16
Raptor Pharmaceutical : Acquisition May Not Be in the Best Interests of RPTP Shareholders	14/09/16
Brower Piven Commences An Investigation Into The Proposed Sale Of Raptor Pharmaceutical Corp. And Encourages Investors To Contact The Firm For Additional Information	12/09/16

Directores	Puesto	Edad	Desde
Paul Hoelscher DFI	Director of Finance/CFO	59	25/10/16
Kim Lee IRC	Investor Relations Contact	-	23/10/14
Françoise de Craecker PRN	Corporate Officer/Principal	62	-

Administradores	Puesto	Edad	Desde
Gregg Lapointe CHM	Chairman	65	01/01/15
Timothy Walbert BRD	Director/Board Member	57	11/04/11
Paul Hoelscher DFI	Director of Finance/CFO	59	25/10/16

Sector

	Varia. 1 de ene.	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-2,31 %	103 mil M
REGENERON PHARMACEUTICALS, INC.	+0,56 %	95,28 mil M
ARGENX SE	+1,69 %	22,15 mil M
BIONTECH SE	-17,37 %	21,02 mil M
GENMAB A/S	-9,30 %	18,15 mil M
WUXI APPTEC CO., LTD.	-41,01 %	16,74 mil M
BEIGENE, LTD.	-14,85 %	16,05 mil M
NEUROCRINE BIOSCIENCES, INC.	+3,21 %	13,68 mil M
SAREPTA THERAPEUTICS, INC.	+33,54 %	12,17 mil M